Premium
Failure of Cilostazol in the Prevention of Ventricular Fibrillation in a Patient with Brugada Syndrome
Author(s) -
ABUD ATILIO,
BAGATTIN DANIEL,
GOYENECHE RAUL,
BECKER CARLOS
Publication year - 2006
Publication title -
journal of cardiovascular electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.193
H-Index - 138
eISSN - 1540-8167
pISSN - 1045-3873
DOI - 10.1111/j.1540-8167.2005.00290.x
Subject(s) - medicine , cilostazol , brugada syndrome , cardiology , ventricular fibrillation , endocardium , sudden cardiac death , reentry , proarrhythmia , repolarization , implantable cardioverter defibrillator , qt interval , aspirin , electrophysiology
The ECG appearance in Brugada syndrome is caused by failure of the dome of the action potential to develop. Increased activity of the I(to) current in epicardial cells generates a transmural gradient with repolarization dispersion between the epicardium and the endocardium in the right ventricular wall, thus favoring the development of VF by a phase 2 reentry mechanism. The efficacy of cilostazol for the management of these arrhythmias has been reported. This drug is a phosphodiesterase inhibitor with positive chronotropic properties, thus blocking outward potassium currents I(to) in the myocardial tissue. We present a patient with Brugada syndrome with an implantable cardioverter defibrillator (ICD), who suffered multiple ICD discharges due to VF during therapy with this drug.